

CAR T-Cell FDA Investigation: Addressing Concerns and Managing CAR T-Cell Referrals for Community Oncologists

Reference List

Abecma. Prescribing Information. Bristol-Myers Squibb Company, Inc. July 2024. Accessed January 8, 2025.

<https://www.fda.gov/media/147055/download>

Abramson JS, Irwin KE, Frigault MJ, et al. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. *Cancer*. 2019;125(21):3692-3698. doi:10.1002/cncr.32411

Abramson JS, Lunning M, Palomba ML. Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: Current and future state of the art. *Am Soc Clin Oncol Educ Book*. 2019;39:446-453. doi:10.1200/EDBK_238693

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. *Lancet*. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0

Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. *Blood*. 2024;143(5):404-416. doi:10.1182/blood.2023020854

Ahmed N, Wesson W, Lutfi F, et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. *Blood Adv*. 2024;8(20):5346-5354. doi:10.1182/bloodadvances.2023012549

Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses. *Blood*. 2024;144(23):2389-2401. doi:10.1182/blood.2024024582

Aucatzyl. Prescribing Information. Autolus, Inc. November 2024. Accessed January 27, 2025.

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fef6986-b988-45e4-8c20-b14f0ef1f538>

Barata A, Hoogland AI, Hyland KA, et al. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. *Psychooncology*. 2021;30(8):1294-1301. doi:10.1002/pon.5674

Beaupierre A, Kahle N, Lundberg R, Patterson A. Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. *J Adv Pract Oncol*. 2019;10(Suppl 3):29-40. doi:10.6004/jadpro.2019.10.4.12

Bishop MR, Kay GE. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists. *Semin Oncol*. 2024;51(3-4):87-94. doi:10.1053/j.seminoncol.2024.02.001

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8


Bishop DC, Clancy LE, Simms R, et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with *piggyBac*-modified CD19 CAR T cells. *Blood*. 2021;138(16):1504-1509. doi:10.1182/blood.2021010813

Breyanzi. Prescribing Information. Bristol-Myers Squibb Company. May 2024. Accessed January 8, 2025.

<https://www.fda.gov/media/145711/download>

Carvykti. Prescribing Information. Janssen Biotech, Inc. April 2024. Accessed January 8, 2025.

<https://www.fda.gov/media/156560/download>



CAR T-Cell FDA Investigation: Addressing Concerns and Managing CAR T-Cell Referrals for Community Oncologists

Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. *Transplant Cell Ther.* 2021;27(3):222-229. doi:10.1016/j.jtct.2020.10.002

Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: What Is next? *Cancers (Basel).* 2023;15(3):663. doi:10.3390/cancers15030663

Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: The efficacy and toxicity balance. *Curr Hematol Malig Rep.* 2023;18(2):9-18. doi:10.1007/s11899-023-00687-7

Cordas dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. *Nat Med.* 2024;30(9):2667-2678. doi:10.1038/s41591-024-03084-6

Dabas P, Danda A. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. *Med Oncol.* 2023;40(9):275. doi:10.1007/s12032-023-02146-y

Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. *Front Immunol.* 2023;14:1113882. doi:10.3389/fimmu.2023.1113882

Dhawale T, Johnson PC, Boateng K, et al. Communication about chimeric antigen receptor T-cell (CAR-T) therapy. *Transplant Cell Ther.* 2024;30(4):402.e1-402.e12. doi:10.1016/j.jtct.2024.01.069

Dreyling M, Fowler NH, Dickinson M, et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. *Blood.* 2024;143(17):1713-1725. doi:10.1182/blood.2023021567

Du M, Hari P, Hu Y, Mei H. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. *Biomark Res.* 2020;8:13. doi:10.1186/s40364-020-00190-8

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. *Am J Hematol.* 2019;94(S1):S3-S9. doi:10.1002/ajh.25418

Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. *Biol Blood Marrow Transplant.* 2019;25(4):e123-e127. doi:10.1016/j.bbmt.2018.12.756


Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. *Blood.* 2019;134(11):860-866. doi:10.1182/blood.2019001694

Ganatra S, Carver JR, Hayek SS, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. *J Am Coll Cardiol.* 2019;74(25):3153-3163. doi:10.1016/j.jacc.2019.10.049

Grant SJ, Grimshaw AA, Silberstein J, et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: A systematic review. *Transplant Cell Ther.* 2022;28(6):294-302. doi:10.1016/j.jtct.2022.03.006

Guffroy A, Jacquel L, Guffroy B, Martin T. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy. *Joint Bone Spine.* 2024;91(5):105702. doi:10.1016/j.jbspin.2024.105702

Hamilton MP, Sugio T, Noordenbos T, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. *N Engl J Med.* 2024;390(22):2047-2060. doi:10.1056/NEJMoa2401361



CAR T-Cell FDA Investigation: Addressing Concerns and Managing CAR T-Cell Referrals for Community Oncologists

Harrison SJ, Nguyen T, Rahman M, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. *Blood*. 2023;142 (Suppl 1):6939. doi:10.1182/blood-2023-178806

Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood*. 2017;130(21):2295-2306. doi:10.1182/blood-2017-06-793141

Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X

Jacobson CA, Munoz J, Sun F, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and meta-analysis. *Transplant Cell Ther*. 2024;30(1):77.e1-77.e15. doi:10.1016/j.jtct.2023.10.017

Jaeger U, Bishop MR, Salles G, et al. Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) treated with tisagenlecleucel in the Juliet trial. *Blood*. 2020;136(Suppl 1):48-49. doi:10.1182/blood-2020-137045

Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019;25(12):2305-2321. doi:10.1016/j.bbmt.2019.08.015

Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. *Blood*. 2023;141(20):2430-2442. doi:10.1182/blood.2022017414

Kamal-Bahl S, Puckett JT, Bagchi I, Miller-Sonet E, Huntington SF. Barriers and solutions to improve access for chimeric antigen receptor therapies. *Immunotherapy*. 2022. doi:10.2217/imt-2022-0037

Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*. 2022;399(10343):2294-2308. doi:10.1016/S0140-6736(22)00662-6

Kisielewski D, Naegele M. Advanced practice nursing and CAR-T cell therapy: Opportunities, challenges and future directions. *Semin Oncol Nurs*. 2024;40(3):151628. doi:10.1016/j.soncn.2024.151628


Krickau T, Naumann-Bartsch N, Aigner M, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. *Lancet*. 2024;403(10437):1627-1630. doi:10.1016/S0140-6736(24)00424-0

Kymriah. Prescribing Information. Novartis Pharmaceuticals Corporation. December 2024. Accessed January 8, 2025. <https://www.fda.gov/media/107296/download>

Leinemann V, Krutter S. 'The last bridge'- How patients experience the CAR T-cell therapy. A qualitative study. *Eur J Oncol Nurs*. 2024;68:102494. doi:10.1016/j.ejon.2023.102494

Liu A. FiercePharma. 'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says. Published November 1, 2024. Accessed January 4, 2025. <https://www.fiercepharma.com/pharma/it-was-good-lesson-fda-reconsiders-car-t-boxed-warning-secondary-cancers-peter-marks-says>

Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. *N Engl J Med*. 2022;386(7):640-654. doi:10.1056/NEJMoa2116133



CAR T-Cell FDA Investigation: Addressing Concerns and Managing CAR T-Cell Referrals for Community Oncologists

Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. *Blood Adv.* 2020;4(19):4898-4911. doi:10.1182/bloodadvances.2020002394

Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med.* 2022;28(10):2124-2132. doi:10.1038/s41591-022-02017-5

Majzner R, Frank MJ, Mount C, et al. CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering. *Blood.* 2020;136(Suppl 1):53-54. doi:10.1182/blood-2020-139605

Mamlouk O, Nair R, Iyer SP, et al. Safety of CAR T-cell therapy in kidney transplant recipients. *Blood.* 2021;137(18):2558-2562. doi:10.1182/blood.2020008759

Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. *Nat Med.* 2022;28(4):658-665. doi:10.1038/s41591-022-01717-2

Mateos M-V, San-Miguel J, Dhakal, et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. 2024 International Myeloma Society Annual Meeting. Abstract OA – 65. <https://clin.larvol.com/abstract-detail/IMW%202024/72592825>

Morschhauser F, Dahiya S, Palomba ML, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. *Nat Med.* 2024;30(8):2199-2207. doi:10.1038/s41591-024-02986-9

Mullard A. FDA approves first CAR T therapy. *Nat Rev Drug Discov.* 2017;16:669. doi:10.1038/nrd.2017.196

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med.* 2021;384(8):705-716. doi:10.1056/NEJMoa2024850

Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US Lymphoma CAR T Consortium. *J Clin Oncol.* 2020;38(27):3119-3128. doi:10.1200/JCO.19.02104


National Comprehensive Cancer Network. B-Cell Lymphomas. V1.2025. Published December 20, 2024. Accessed January 9, 2025. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

National Comprehensive Cancer Network. Multiple Myeloma. V1.2025. Published September 17, 2024. Accessed January 9, 2025. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities. V1.2025. Published December 20, 2024. Accessed January 8, 2025. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf


Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. *Blood.* 2023;141(19):2307-2315. doi:10.1182/blood.2022018893

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. *N Engl J Med.* 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447



CAR T-Cell FDA Investigation: Addressing Concerns and Managing CAR T-Cell Referrals for Community Oncologists

- Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. *Blood Adv.* 2021;5(20):4149-4155. doi:10.1182/bloodadvances.2020003848
- Rice J, Nagle S, Randall J, Hinson HE. Chimeric antigen receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and approach to treatment. *Curr Treat Options Neurol.* 2019;21(8):40. doi:10.1007/s11940-019-0580-3
- Riedell PA, Downs C, Boehmer L, Ebmeier J, Porter D, Williams A. If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary. *Transplant Cell Ther.* 2024;30(1):14-16. doi:10.1016/j.jtct.2023.10.019
- Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene autoleucl in adults with B-cell acute lymphoblastic leukemia. *N Engl J Med.* 2024;391(23):2219-2230. doi:10.1056/NEJMoa2406526
- Ruella M. CAR-T therapy for all: Addressing the access gap. *Transplant Cell Ther.* 2024;30(7):644-645. doi:10.1016/j.jtct.2024.06.011
- San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. *N Engl J Med.* 2023;389(4):335-347. doi:10.1056/NEJMoa2303379
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucl in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med.* 2019;380(1):45-56. doi:10.1056/NEJMoa1804980
- Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucl for relapsed/refractory multiple myeloma. *Blood.* 2025;145(1):85-97. doi:10.1182/blood.2024025945
- Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer J.* 2021;11:69. doi:10.1038/s41408-021-00459-7
- Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR-T cell therapy: A breakthrough in traditional cancer treatment strategies. *Mol Med Rep.* 2024;29(3):47. doi:10.3892/mmr.2024.13171
- Tecartus. Prescribing Information. Kite Pharma, Inc. June 2024. Accessed January 8, 2025. <https://www.fda.gov/media/140409/download>
- Tix T, Alhomoud M, Shouval R, et al. Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. *Clin Cancer Res.* 2024;30(20):4690-4700. doi:10.1158/1078-0432.CCR-24-1798
- Tsimberidou AM, Fountzilias E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treat Rev.* 2020;86:102019. doi:10.1016/j.ctrv.2020.102019
- US Food & Drug Administration. FDA approval brings first new therapy to the United States. Published August 30, 2017. Accessed January 4, 2025. <https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states>
- US Food & Drug Administration. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Published November 28, 2023. Accessed January 8, 2025. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous>



CAR T-Cell FDA Investigation: Addressing Concerns and Managing CAR T-Cell Referrals for Community Oncologists

US Food & Drug Administration. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Published April 18, 2024. Accessed January 8, 2025. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed>

US Food & Drug Administration. Risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor (CAR) T cell immunotherapies modified to minimize burden on healthcare delivery system. Published June 26, 2024. Accessed January 11, 2025. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor-car-t-cell>

Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. *N Engl J Med*. 2024;390(7):584-586. doi:10.1056/NEJMp2400209

Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347

Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. *J Clin Oncol*. 2023;41(3):555-567. doi:10.1200/JCO.21.02370

Willyard C. Do cutting-edge CAR-T-cell therapies cause cancer? What the data say. *Nature*. 2024;629(8010):22-24. doi:10.1038/d41586-024-01215-0

Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). *Haematologica*. 2020;105(2):297-316. doi:10.3324/haematol.2019.229781

Yescarta. Prescribing Information. Kite Pharma, Inc. June 2024. Accessed January 8, 2025. <https://www.fda.gov/media/108377/download>

Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. *Front Immunol*. 2023;14:1101495. doi:10.3389/fimmu.2023.1101495